Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 10,000 shares at $35.36 ($359K) on 2025-04-07, disclosed to the SEC on 2025-04-10.
Scheduled sale ($359k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.36 | 2,200 | $78K | 21.6% |
| 2 | $36.05 | 3,750 | $135K | 37.6% |
| 3 | $36.05 | 3,750 | $135K | 37.6% |
| 4 | $36.93 | 100 | $4K | 1.0% |
| 5 | $37.92 | 200 | $8K | 2.1% |
| Total | $35.94 avg | 10,000 |
| $359K |
| 100% |
| Filing → |
| AKRO | SELL | 2025-09-10 | $1.1M | — | Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |